Discontinuation of Corex cough syrup sale slumps Pfizer share
Mumbai: Shares of pharmaceutical firm Pfizer slumped 9 per cent as the company has discontinued the manufacture and sale of popular cough syrup Corex with immediate effect.
The stock slipped 8.67 per cent to settle at Rs 1,760.80 on BSE. During the day, it tumbled 9 per cent to Rs 1,753.10.
At NSE, shares of the company dived 8.99 per cent to close at Rs 1,754.70.
The company's market valuation fell by Rs 763.74 crore to Rs 8,055.26 crore.
Pfizer has discontinued manufacture and sale of Corex cough syrup with immediate effect after the government banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup.
"This is to inform you that the Government of India vide Notification dated March 10, 2016 has prohibited the manufacture for sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect," Pfizer said in a BSE filing.
In view of this, the company has discontinued the manufacture and sale of the drug with immediate effect, it said.
"The above prohibition is likely to have an adverse impact on the revenue and profitability of the company Corex recorded sale of Rs 176 crore for the nine month period ended December 31, 2015," the company said.
The stock slipped 8.67 per cent to settle at Rs 1,760.80 on BSE. During the day, it tumbled 9 per cent to Rs 1,753.10.
At NSE, shares of the company dived 8.99 per cent to close at Rs 1,754.70.
The company's market valuation fell by Rs 763.74 crore to Rs 8,055.26 crore.
Pfizer has discontinued manufacture and sale of Corex cough syrup with immediate effect after the government banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup.
"This is to inform you that the Government of India vide Notification dated March 10, 2016 has prohibited the manufacture for sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect," Pfizer said in a BSE filing.
In view of this, the company has discontinued the manufacture and sale of the drug with immediate effect, it said.
"The above prohibition is likely to have an adverse impact on the revenue and profitability of the company Corex recorded sale of Rs 176 crore for the nine month period ended December 31, 2015," the company said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd